Revelation Biosciences Inc (REVB) — Cash Flow-to-Debt Ratio
Revelation Biosciences Inc (REVB) has a Cash Flow-to-Debt Ratio of -1.56x as of March 2026, meaning its operating cash flow of $-3.21 Million could theoretically repay -2% of its total liabilities ($2.06 Million) in one year. See REVB cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Revelation Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Revelation Biosciences Inc across 10 annual periods. Also explore how fast is Revelation Biosciences Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Revelation Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Revelation Biosciences Inc. For market capitalisation and broader financial context, see REVB market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.04x | $-8.27 Million | $2.72 Million | ▲ +68.3% |
| 2024 | -9.57x | $-18.32 Million | $1.91 Million | ▼ -631.2% |
| 2023 | -1.31x | $-7.29 Million | $5.56 Million | ▲ +48.1% |
| 2022 | -2.52x | $-11.22 Million | $4.45 Million | ▲ +51.3% |
| 2021 | -5.18x | $-11.09 Million | $2.14 Million | ▼ -2810.4% |
| 2020 | -0.18x | $-215.07K | $1.21 Million | ▼ -100.0% |
| 2019 | 1561.67x | $41.09 Million | $26.31K | ▲ +10499175.7% |
| 2018 | 0.01x | $32.58 Million | $2.19 Billion | ▲ +17.2% |
| 2017 | 0.01x | $24.25 Million | $1.91 Billion | ▲ +88.8% |
| 2016 | 0.01x | $11.60 Million | $1.73 Billion | — |